Ablynx, a Sanofi company, is engaged in the development of Nanobodies®, proprietary therapeutic proteins based on single-domain antibody fragments, which combine the advantages of conventional antibody drugs with some of the features of small-molecule drugs. Nanobodies have potential uses in the treatment of a range of serious and life-threatening human diseases. Ablynx advances a portfolio of Nanobody-based therapeutic programs in several major disease areas, including inflammation, haematology, immuno-oncology and oncology. The acquisition of Ablynx (June 2018) continues Sanofi’s commitment to breakthrough innovation, focused on technologies addressing multiple disease targets with single multi-specific molecules. Sanofi is committed to accelerating Ablynx’s Nanobody development programmes.
View Top Employees from AblynxWebsite | https://www.ablynx.com |
Revenue | $138.5 million |
Funding | $227.6 million |
Employees | 203 (203 on RocketReach) |
Founded | 2001 |
Address | 21 Technologiepark Zwijnaarde, Gent, Flanders 9052, BE |
Phone | (329) 262-0000 |
Fax | (329) 262-0001 |
Technologies |
JavaScript,
HTML,
Twitter
+48 more
(view full list)
|
Industry | Biotechnology Research, Business Services General, Discovery, Business Services, Research and Drug Development |
Keywords | Therapeutic Activities, Inflammatory Diseases, Oncology, Immuno-Oncology |
SIC | SIC Code 87 Companies, SIC Code 283 Companies, SIC Code 873 Companies, SIC Code 28 Companies |
NAICS | NAICS Code 325 Companies, NAICS Code 3254 Companies, NAICS Code 32541 Companies, NAICS Code 32 Companies |
Looking for a particular Ablynx employee's phone or email?
The Ablynx annual revenue was $138.5 million in 2024.
Malgorzata Ciesiolka is the Director Business Development of Ablynx.
203 people are employed at Ablynx.
Ablynx is based in Gent, Flanders.
The NAICS codes for Ablynx are [325, 3254, 32541, 32].
The SIC codes for Ablynx are [87, 283, 873, 28].